27 April 2026
Access to a well‑characterized tool compound library provides a strong foundation for early biological discovery. Through opnMe, our freely available preclinical molecules have enabled scientists worldwide to test and validate their research hypotheses, contributing to more than 250 independent, peer‑reviewed publications to date.
To further enable systematic screening and profiling approaches for the validation of novel, disease‑relevant biological hypotheses, we are now making the entire opnMe molecule library available for a limited time as a single, ready‑to‑screen package.
To access this valuable research tool, we invite scientists to address the following question with a research proposal:
How would you leverage the entire opnMe molecule library to address new biological questions in the context of human disease as part of screening and profiling activities?
The collection comprises 176 high‑quality, well‑characterized molecules, including 99 active compounds and 77 relevant negative controls, and is provided free of charge to selected scientists worldwide.
This unique opportunity is designed to support library‑wide screening and profiling strategies. By accessing molecules with well‑understood modes of action and selectivity, researchers can run phenotypic and profiling screens across the full collection, generate robust signatures across morphological, functional, and multi‑omics readouts, and derive data‑driven insights into disease‑relevant biology.
Submit your proposal by June 17, 2026 (11:59 pm PST) for a chance to access the full opnMe molecule library and accelerate your research. All research proposals will be evaluated by an internal research review team. Winning proposals will receive the opnMe compound library to pursue their research independently. Intellectual ownership of all resulting data will remain with the submitting scientists, who are encouraged to publish their findings in high‑impact, peer‑reviewed journals.
No registration required
Subscribe to our newsletter to stay updated as we add new molecules to opnMe.com.
About our call for “Molecules for Collaboration”:
On opnMe, we are now offering access to our entire “molecule‑to‑order” library as a single, ready‑to‑screen package to support systematic screening and profiling studies. Submit your proposals by June 17, 2026. Learn more…
About opnMe:
opnMe.com, the open science portal of Boehringer Ingelheim, fosters science and collaboration initiatives in areas of high unmet medical need. Our molecules are provided to the scientific community either free of charge as “Molecules to Order” or applied for via scientific research submissions as “Molecules for Collaboration”. With our “opn2EXPERTS” and “techMATCH” calls, we enlist scientific advice on key scientific topics to fuel further drug discovery and deliver novel solutions that benefit unmet patient needs. Our "opn2TALENTS" postdoc grants at one of our research sites offer opportunities for high-level talents to propose innovative approaches for precisely defined scientific questions.